1.Cold chain time- and temperature-controlled transport of vaccines: a simulated experimental study
Chun Zheng NG ; Yen Loong LEAN ; Siang Fei YEOH ; Qi Ying LEAN ; Kah Seng LEE ; Amal Khalil SULEIMAN ; Kai Bin LIEW ; Yaman Walid KASSAB ; Yaser Mohammed AL-WORAFI ; Long Chiau MING
Clinical and Experimental Vaccine Research 2020;9(1):8-14
2.Comparison of Microemulsion and Solvent Evaporation Technique for Solubility Enhancement of Amlodipine Besylate
Raja Nurul Batrisyia Hamzah ; Long Chiau Ming ; A.B.M. Helal Uddin ; Zaidul Islam Sarker ; Kai Bin Liew ; Yik Ling Chew
Malaysian Journal of Medicine and Health Sciences 2022;18(No.4):135-140
Introduction: Amlodipine besylate is a calcium channel blocker indicated for hypertension and angina. It is described as slightly soluble in water and due to its limited solubility, it may result in poor bioavailability. The aim of
this study is to enhance the solubility of amlodipine besylate using solvent evaporation method and microemulsion
technique and to compare the two methods. Method: Solid dispersions (SD) of amlodipine besylate were developed
by employing solvent evaporation method. PEG6000 was the polymer of choice and different drug:polymer ratios
were used. Evaluation of the prepared SDs include solubility studies, dissolution studies and scanning electron microscopy (SEM). As for the microemulsion technique, microemulsions were prepared by phase titration method and
the optimized microemulsion formulation was then characterized for solubility studies and dissolution studies. Results: SD3 with drug:polymer ratio of 1:4 achieved the highest solubility which was 96.97 mg/ml ± 0.92 whereas the
solubility of the optimized microemulsion was found to be 112.54 mg/ml ± 0.92. In solvent evaporation method, as
the drug:polymer ratio increases, the solubility and dissolution rate of SDs increases. Conclusion: The two methods
had significantly enhance the solubility of amlodipine besylate however the microemulsion technique showed better
solubility profile.
3. Convalescent plasma: A potential therapeutic option for COVID-19 patients
Swee Li NG ; Bey Hing GOH ; Tsuey Ning SOON ; Wei Hsum YAP ; Yin-Quan TANG ; Kai Bin LIEW ; Ya Chee LIM ; Long Chiau MING ; Bey Hing GOH
Asian Pacific Journal of Tropical Medicine 2020;13(11):477-486
The new coronavirus disease (COVID-19) outbreak has challenged us to take unprecedented steps to bring this pandemic under control. In view of the urgency of this situation, convalescent plasma which was used in previous coronavirus outbreaks has emerged as one of the treatment options in this current pandemic. This is mainly due to the fact that convalescent plasma has been studied in a few case series with promising outcomes. In addition, on-going large clinical trials aimed to further evaluate the effectiveness, safety, and optimal dosage, duration and timing of administration of convalescent plasma are indeed revealing a certain level of promising results. Therefore, this article aims to provide an overview of possible mechanisms of actions of convalescent plasma, its benefits and its level of usage safeness by summarizing the existing evidence on the use of convalescent plasma in COVID-19 patients.
4.Orally Disintegrating Film: A Review of Its Formulation and Manufacturing Method
Kai Bin Liew ; Ganesan Gobal ; Hanifah Mohd Rofiq ; Hiu Ching Phang ; Siew-Keah Lee ; Long Chiau Ming ; A.B.M. Helal Uddin ; Yik Ling Chew ; Vijayakumar Lakshminarayanan
Malaysian Journal of Medicine and Health Sciences 2023;19(No.6):297-303
Oral route drug delivery system is still considered as the most convenient and patient friendly drug delivery route.
Over the decades, many research has been performed to improve the functionality oral dosage form. Orally disintegrating film (ODF) is a newer oral drug delivery system, which is in the form of a thin film that will disintegrate in
the oral cavity within a matter of seconds. The aim of this review paper is to recap ODF, its benefits, formulation
contents and manufacturing method. With more research and development work has been conducted on ODF, the
dosage form is expected to be manufactured and scaled up to be commercializable products to be sold in the market.